MDT

98.85

+0.46%↑

145.27

-1.04%↓

VEEV

219.02

+0.28%↑

HQY

87.05

+2.06%↑

NEOG

9.56

+1.59%↑

MDT

98.85

+0.46%↑

145.27

-1.04%↓

VEEV

219.02

+0.28%↑

HQY

87.05

+2.06%↑

NEOG

9.56

+1.59%↑

MDT

98.85

+0.46%↑

145.27

-1.04%↓

VEEV

219.02

+0.28%↑

HQY

87.05

+2.06%↑

NEOG

9.56

+1.59%↑

MDT

98.85

+0.46%↑

145.27

-1.04%↓

VEEV

219.02

+0.28%↑

HQY

87.05

+2.06%↑

NEOG

9.56

+1.59%↑

MDT

98.85

+0.46%↑

145.27

-1.04%↓

VEEV

219.02

+0.28%↑

HQY

87.05

+2.06%↑

NEOG

9.56

+1.59%↑

Home・Aandelen Lijst・VolitionRX Ltd

VolitionRX Ltd

Open

0.28 -3.45

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

0.28

Max

0.3

Belangrijke statistieken
By Trading Economics
Inkomsten	936K -5.4M
Verkoop	221K 627K
Winstmarge	-857.414
Werknemers	75
EBITDA	1.3M -4.2M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+603.13% upside

Dividenden
By Dow Jones
Volgende Winsten	30 mrt 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-5.1M 42M
Vorige openingsprijs	3.73
Vorige sluitingsprijs	0.28

VolitionRX Ltd Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 jan 2026, 22:41 UTC

Acquisities, Fusies, Overnames

Canadian Natural Resources, Tourmaline File Deal Notice With Antitrust Regulator

15 jan 2026, 00:00 UTC

Winsten

Welcome to Greenland, an Economy Reliant on Subsidies and Shrimp -- WSJ

14 jan 2026, 23:47 UTC

Marktinformatie

Oil Slips After Trump Appears to Tilt Away From Military Action in Iran -- Market Talk

14 jan 2026, 23:44 UTC

Marktinformatie

Nikkei May Decline After Hitting Record Highs; Election in Focus -- Market Talk

14 jan 2026, 23:39 UTC

Marktinformatie

ANZ's New Bull Still Sees Valuation Gap to Peers -- Market Talk

14 jan 2026, 23:32 UTC

Marktinformatie

Gold Declines on Likely Technical Correction, Possible Profit-Taking -- Market Talk

14 jan 2026, 22:56 UTC

Acquisities, Fusies, Overnames

Soho House Amends Rollover and Support Agreements With Broad Street Principal Investments and Others

14 jan 2026, 22:53 UTC

Acquisities, Fusies, Overnames

Soho House: Apollo Global Management and Goldman Sachs Asset Management Amend Debt Commitment

14 jan 2026, 22:17 UTC

Marktinformatie

Global Equities Roundup: Market Talk

14 jan 2026, 22:17 UTC

Marktinformatie

WiseTech's Revenue Growth Drivers Attract Scrutiny -- Market Talk

14 jan 2026, 22:09 UTC

Winsten

CITIC Securities: Uptrend in China Capital Markets Supported Results >600030.SH

14 jan 2026, 22:08 UTC

Winsten

CITIC Securities 2025 Oper Rev CNY74.83B Vs. CNY58.12B >600030.SH

14 jan 2026, 22:08 UTC

Winsten

CITIC Securities 2025 Net CNY30.05B Vs. Net CNY21.57B >600030.SH

14 jan 2026, 21:53 UTC

Acquisities, Fusies, Overnames

WuXi XDC Expects 2025 Net to Increase Over 38% on Year

14 jan 2026, 21:53 UTC

Acquisities, Fusies, Overnames

WuXi XDC Expects 2025 Revenue to Increase More Than 45% on Year

14 jan 2026, 21:52 UTC

Acquisities, Fusies, Overnames

WuXi XDC Announces Positive Profit Alert for 2025

14 jan 2026, 21:51 UTC

Acquisities, Fusies, Overnames

Citigroup Acting as Financial Advisor to WuXi XDC

14 jan 2026, 21:51 UTC

Acquisities, Fusies, Overnames

WuXi XDC: Aims to Keep Listing Status of BioDlink

14 jan 2026, 21:51 UTC

Acquisities, Fusies, Overnames

WuXi XDC: Company to Finance BioDlink Shares Acquisition via Internal Resources

14 jan 2026, 21:50 UTC

Marktinformatie

Winsten

Financial Services Roundup: Market Talk

14 jan 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

14 jan 2026, 21:49 UTC

Acquisities, Fusies, Overnames

WuXi XDC: BioDlink Offer to Cost HK$2.79B

14 jan 2026, 21:48 UTC

Acquisities, Fusies, Overnames

WuXi XDC Offers to Pay HK$4.00 for Each BioDlink International Share

14 jan 2026, 21:48 UTC

Acquisities, Fusies, Overnames

WuXi XDC Makes Cash Offer for BioDlink International

14 jan 2026, 21:13 UTC

Marktinformatie

Oil Retreats Late After Trump Comments on Iran -- Market Talk

14 jan 2026, 20:30 UTC

Marktinformatie

Winsten

Danaher's Preliminary 4Q Seen as Promising -- Market Talk

14 jan 2026, 20:13 UTC

Marktinformatie

U.S. Natural Gas Futures Sink Ahead of Storage Report -- Market Talk

14 jan 2026, 20:08 UTC

Marktinformatie

Oil Futures Extend Rally on Iran Tensions -- Market Talk

14 jan 2026, 19:33 UTC

Marktinformatie

Nutrien Seen as Winner in Tighter 2026 Potash Market, Higher Prices -- Market Talk

14 jan 2026, 19:06 UTC

Marktinformatie

Winsten

Wells Fargo Says Customers, Economy Remain Resilient -- Market Talk

Peer Vergelijking

Prijswijziging

VolitionRX Ltd Prognose

Koersdoel

By TipRanks

603.13% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 2.25 USD 603.13%

Hoogste 3 USD

Laagste 1.5 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor VolitionRX Ltd - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

3 ratings

Buy

Hold

Sell

Gebaseerd op 3 analisten die aandelenratings hebben gegeven aan VolitionRX Ltd - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over VolitionRX Ltd

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.